Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in hemodynamically stable patients with worsening heart failure
NL-OMON46513Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotagliflozin in heart failure (HF) and Acute Heart Failure (AHF) (3 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability and Plasma volume change. Started Sep 2018; status: active, not recruiting.
02
Drugs
sotagliflozin
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NL-OMON46513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46513.